NIH Awards UP Oncolytics $2.5 Million for Glioblastoma Therapy Development

The National Institutes of Health (NIH) has awarded UP Oncolytics $2.5 million through Phase II SBIR Fast-Track funding to advance an engineered Zika-virus therapy for glioblastoma. The two-year effort is focused on completing the preclinical development package and preparing an Investigational New Drug (IND) application for submission to the Food and Drug Administration (FDA). This award follows a $500,000 Phase I SBIR award from the same mechanism, providing continuity between early-stage research and the next set of development milestones. The funding is a research grant, not a solicitation or contract opportunity, and the FDA is the intended regulatory recipient of the application rather than the funding agency.

The program addresses a serious unmet medical need. The source reports that glioblastoma kills most patients within 15 months of diagnosis, with approximately 13,000 Americans diagnosed each year and only about 5% surviving five years. The standard Stupp protocol—radiation combined with temozolomide—reported median overall survival of 14.6 months when it established the benchmark in 2005. The source characterizes current median survival as approximately 15 months, suggesting limited improvement over the intervening decades. For government contractors, this context points to sustained public and private interest in oncology research, but it does not establish an imminent government buying requirement or guarantee that the NIH-funded program will reach clinical testing.

UP Oncolytics’ approach uses Zika’s ability to cross the blood-brain barrier, a membrane that limits the delivery of many conventional treatments to brain tumors. The company is adapting the virus to target and destroy glioblastoma cells while sparing healthy tissue; its preclinical studies have shown activity against tumors, according to the source. The FDA has granted Orphan Drug Designation to one of the company’s oncolytic virus strains for malignant gliomas. That designation can provide development incentives, but it is not evidence of efficacy, an FDA approval, or authorization to begin a clinical trial. The IND is the next concrete regulatory milestone: submission would allow the FDA to review whether the safety data for an attenuated, therapeutically re-engineered Zika strain supports exposing patients to the candidate.

The development work may create downstream needs for specialized suppliers if UP Oncolytics proceeds toward human trials. Relevant capabilities could include preclinical testing, research services, viral-vector or biologics manufacturing, quality systems, regulatory support, and clinical-trial operations. No subcontract, task order, procurement notice, or other vendor opportunity is announced in this signal, so contractors should treat these as potential future areas to monitor rather than current pipeline opportunities. The two-year funding period and the stated endpoint—completion of the preclinical package and IND preparation—offer useful milestones for companies evaluating strategic fit, partnership prospects, or relevant government-funded research activity.

The competitive environment also matters. The source notes that other oncolytic virus programs, including DNX-2401 combined with pembrolizumab in recurrent glioblastoma, have reached clinical testing. UP Oncolytics is therefore entering an active research field, and its proposed distinction is the Zika viral vector’s neurotropism and potential to reach brain tumors. For GovCon teams, the near-term watch item is progress toward IND submission and any subsequent regulatory decision, not an assumed award pipeline. Future opportunities would depend on the research outcome, regulatory review, and the company’s decisions about external support; none is committed by the NIH award itself.

• NIH awarded $2.5 million to UP Oncolytics through Phase II SBIR Fast-Track funding for a two-year development effort.
• The award builds on an earlier $500,000 Phase I SBIR award from the same funding mechanism.
• Funded work is aimed at completing preclinical development of an engineered Zika-virus therapy for glioblastoma.
• The stated regulatory milestone is preparation of an Investigational New Drug application for the FDA; the FDA is not the funding agency.
• The source describes Zika’s ability to cross the blood-brain barrier as the biological rationale for the therapy’s potential use against brain tumors.
• FDA Orphan Drug Designation applies to one of the company’s oncolytic virus strains for malignant gliomas; the designation is not approval or proof of efficacy.
• The source cites approximately 13,000 U.S. glioblastoma diagnoses annually, median survival of about 15 months, and five-year survival of roughly 5%.
• Other oncolytic virus programs, including DNX-2401 with pembrolizumab in recurrent glioblastoma, have reached clinical testing, indicating an active competitive field.
• No procurement or subcontracting opportunity is announced; research, testing, manufacturing, regulatory, and trial-support firms can monitor the program for possible later needs.
• Contractors should track progress against the two-year preclinical and IND-preparation milestones before treating the work as a prospective business opportunity.